Home
OSTX
OSTX News

Latest OS THERAPIES INCORPORATED (OSTX) News on July 29, 2025

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Business Wire

a month ago

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

Business Wire

a month ago

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

PR Newswire

2 months ago

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

Business Wire

2 months ago

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire

2 months ago

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

Business Wire

2 months ago

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

MT Newswires

3 months ago

OS Therapies Receives US Patent Covering Cancer Immunotherapy Platform

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

Business Wire

3 months ago

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

Business Wire

3 months ago

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

OS Therapies FDA Meeting Request Granted

Business Wire

3 months ago

OS Therapies FDA Meeting Request Granted

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

Business Wire

4 months ago

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

MT Newswires

4 months ago

OS Therapies Finalizes Acquisition of Advaxis Assets From Ayala Pharmaceuticals

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

Business Wire

4 months ago

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

Business Wire

4 months ago

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

Business Wire

4 months ago

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

Business Wire

4 months ago

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

Business Wire

4 months ago

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

Business Wire

4 months ago

OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts

Insider Monkey

4 months ago

OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

Business Wire

4 months ago

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

Business Wire

5 months ago

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

Business Wire

5 months ago

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

5 months ago

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

Business Wire

5 months ago

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

MT Newswires

5 months ago

OS Therapies Forms Drug Conjugates Unit, Reviews Options for Tunable ADC, Drug Conjugates Platforms

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

Business Wire

5 months ago

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

Business Wire

5 months ago

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

MT Newswires

5 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

Benzinga

5 months ago

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

MT Newswires

5 months ago

OS Therapies Says It Signed Manufacturing Deal for Lead Candidate OST-HER2

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

Business Wire

5 months ago

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

OS Therapies Provides Corporate Update

Business Wire

6 months ago

OS Therapies Provides Corporate Update

RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis

ACCESS Newswire

6 months ago

RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis

OS Therapies to acquire listeria programs from Ayala Pharmaceuticals

TipRanks

6 months ago

OS Therapies to acquire listeria programs from Ayala Pharmaceuticals

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline

Business Wire

6 months ago

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline

OS Therapies price target raised to $15 from $8 at Maxim

TipRanks

6 months ago

OS Therapies price target raised to $15 from $8 at Maxim

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Business Wire

6 months ago

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

7 months ago

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

OS Therapies Announces Closing of $6 Million Private Placement

Business Wire

7 months ago

OS Therapies Announces Closing of $6 Million Private Placement

OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online

NewMediaWire

7 months ago

OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online

OS Therapies to sell 1.5M units at $4.00 in private placement

TipRanks

7 months ago

OS Therapies to sell 1.5M units at $4.00 in private placement

OS Therapies Announces Pricing of $6 Million Private Placement

Business Wire

7 months ago

OS Therapies Announces Pricing of $6 Million Private Placement

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire

8 months ago

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

OS Therapies to Present at The Spartan Capital Investor Conference

Business Wire

9 months ago

OS Therapies to Present at The Spartan Capital Investor Conference

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

Business Wire

9 months ago

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Business Wire

9 months ago

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

OS Therapies to Present at the LD Micro Main Event XVII

Business Wire

9 months ago

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Business Wire

9 months ago

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Business Wire

10 months ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Business Wire

a year ago

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

ACCESSWIRE

a year ago

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

Business Wire

a year ago

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

Business Wire

a year ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

Business Wire

a year ago

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

OS Therapies Clarifies CUSIP of Common Stock

Business Wire

a year ago

OS Therapies Clarifies CUSIP of Common Stock

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

Business Wire

a year ago

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

OS Therapies Reports Second Quarter 2024 Financial Results

ACCESSWIRE

a year ago

OS Therapies Reports Second Quarter 2024 Financial Results

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

a year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

ACCESSWIRE

a year ago

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

Share on Social Networks: